A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...
With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...
NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...
Hosted on MSN
A generative AI platform for mRNA therapeutics
Raina Biosciences Inc. (Raina), an mRNA technology and therapeutics company, has released data from its generative AI platform in Science. The data supports Raina's pioneering approach to mRNA design ...
IBM and Moderna have achieved a groundbreaking milestone by simulating the longest mRNA pattern without the use of AI, instead leveraging the power of quantum computing. This collaboration marks a ...
The mRNA vaccine drug development market presents growth opportunities through increased investment, diverse therapeutic applications, and scalable production demand. Key prospects include strategic ...
At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback